Cannabis Science, Inc (CBIS)

cannabis_print_logoOne of the biggest names in cannabis research and development, Cannabis Science, Inc is a biotech company that creates cannabinoid-based formulations for a variety of medical conditions. Among these are eight types of cancer, autism, attention deficit hyperactivity disorder (ADHD), and other neurobehavioral disorders.

The company has two major programs on cannabinoid medicines. One is on CS-TATI-1, targeted for patients with drug-resistant HIV strains. The development of this product particularly looks at an HIV-related cancer called Epidemic AIDS-Related Kaposi Sarcoma. Meanwhile, the other program is on CS-S/BCC-1, producing cannabinoid-based extracts that can be applied topically on skin cancer lesions. The company has seen some success in patients who have self-administered this treatment, and is now discussing it with FDA specialists.

Aside from its scientific programs and innovations, Cannabis Science also produces online videos promoting education on medical marijuana. It has also been a partner of various key players in the marijuana industry, including the medical cannabis consulting firm Michigan Green Technologies and the medical dispensing solutions company Medbox.

Cannabis Science was founded in 2000 as National Healthcare Technology. In 2009, it was reestablished as Cannabis Science and then went into public trading, with a new drive to advance its research on the pharmaceutical potential of marijuana. The company’s present CEO is Dorothy H. Bray, PhD, who was formerly the Global Director of HIV Research at GlaxoSmithKline. Other Cannabis Science executives include Chad S. Johnson as COO, Robert Kane as CFO, and Richard Ogden, PhD as Chief Scientific Officer.

Based in Cannabis Science is being traded in the OTC market as CBIS and is valued at USD 61.64 M. It is listed under the Medical Laboratories & Research industry, in the Healthcare sector.

Cannabis Science, Inc

6946 North Academy Boulevard
Suite B #254
Colorado Springs, CO 80918

Email: info@cannabisscience.com
Phone: +1 (888) 889-0888
Fax: +1 (866) 943-5085
Website: http://www.cannabisscience.com/


Yahoo! Finance: CBIS News

Latest Financial News for CBIS

Cannabis Science Issues 2019 Guidance Report; Under SEC Sanctions the Company Goes Private as It Enters Into Step (2) of Its Growth Transition, Enabling Full Transparency and Revenue Growth

Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has agreed to go private under sanctions by the U.S. Securities and Exchange Commission (“SEC”). All Cannabis Science shareholders and their shareholdings will remain intact under the same name and entity, Cannabis Science Inc., a Nevada Corporation. Cannabis Science shares will no longer be quoted or traded on any stock market exchange.

Cannabis Science Enters Transition Stage as Trading of the Company’s Shares is Halted; The Company Will Continue to Implement Its Growth Strategy and Resolve All Outstanding Fully Reporting Requirements

IRVINE, CA, Sept. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that it is entering a transition stage as trading of the Company’s shares is halted. Cannabis Science will continue to implement its corporate growth strategy and intends to resolve all outstanding regulatory reporting and filing requirements as it goes through its transition. “I can confirm that I found out yesterday that the trading of Cannabis Science’s shares has been halted by regulatory authorities - clearly the paperwork states ‘due to the financials not being filed as a fully-reporting issuer’.  While this is not a favorable situation, we are already addressing this matter directly with the authorities to protect the interests of our shareholders and stakeholders,” states Raymond C. Dabney, President, C.E.O. and Co-Founder of Cannabis Science.

The Week In Cannabis: Moves From The DEA, FDA, USDA; New York Fashion Week; And Quarterly Reports

A series of earnings reports from big companies including Slang Worldwide Inc (OTC: SLGWF) and TILT Holdings Inc (OTC: SVVTF) provided evidence that “the slow rollout of Massachusetts' recreational licenses has finally hit the earnings of cannabis companies who were slow to recognize the effects,” Green Market Report CEO Debra Borchardt told Benzinga. In other news, we found out that a weed-themed show is hitting the runway at the New York Fashion Week, the product of a collaboration between bold fashion designer Korto Momolu —featured on the show "Project Runway" —and Women Grow, the largest networking organization for women in the cannabis and hemp industries. "To sum it up in one phrase: it's 'for women, by women,'" Momolu told Benzinga.

Cannabis Science Partners With CDN Firm NHS Industries to Launch the CBIS CDN Economic Development Plan; CBIS to Use Its Relations With the Harvard International Phytomedicines and Medical Cannabis Institute and Other Leading Institutions

IRVINE, CA, Aug. 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the Company has signed a joint venture agreement with a Canadian public company, NHS Industries, Ltd. NHS Industries (CSE: (NHS), (NNHHF)). The group will focus on job creation, deliver and develop public and private access educational content, and research various delivery platforms for medical cannabinoid-related products and services, all based on the CBIS Economic Development Plan for Canada, (CBIS/CDN EDP). The new Canadian-based partnership will expand Cannabis Science’s existing operations into Canada through its CDN EDP.

The Week In Cannabis: CannTrust Continues Fall, Earnings A Mixed Bag, Clio Goes Green

CannTrust Holdings Inc (NYSE: CTST) plummeted last week after issuing a press release acknowledging it hat failed a Health Canada inspection in July. Meanwhile, Greenlane Holdings, Inc. (NASDAQ: GNLN) posted a net sales increase of 30.6% in the second quarter of 2019, with sales totaling $53 million, and Canopy Growth Corp (NYSE: CGC) tumbled after reporting an adjusted EBITDA loss of CA$92 million ($69.1 million), up from CA$22.5 million ($16.8 million) last year. Commenting on Canopy’s results Patrick Sanders, assistant managing editor for investing at U.S. News & World Report, told Benzinga, “The markets overreacted when CGC reported losing more than $1 billion in the last quarter.